Unlocking transformation: Dr Emran Ghaffar Khan reveals the power of Zepbound/Mounjaro in revolutionising weight loss

Recently, Dr Emran Ghaffar Khan, a distinguished Consultant Endocrinologist and Director of Kings Institute of Diabetes, Endocrinology, and Obesity (KIDEO) in Dubai Hills, shared insights on the groundbreaking weight loss medication, Zepbound (Mounjaro). With over 30 years of experience in the field, Dr Emran Khan emphasised the importance of understanding this revolutionary drug.

There has been a lot of discussion and recently in the process about this new medication. He explained that Mounjaro was available for more than one year and was only licensed for type 2 diabetes and now this has been given a license for weight management for patients who were not diabetic. In some countries, the same medication Mounjaro has been rebranded for the purpose of weight management and it is been called Zepbound. It has exactly the same ingredient Tirzepitide in both of them. It will remain available in UAE under the name Mounjaro.

There have been a lot of recent discussions about this new breakthrough in obesity. Prior to these new medications, there were very limited options available apart from bariatric surgery. It is the first time that we have medications which are for addressing similar results as bariatric surgery and reduce the health risks caused by obesity significantly.

Overview of Zepbound/Mounjaro:

Zepbound, a rebranded version of Tirzepitide (Mounjaro), is a medication initially licensed for Type 2 Diabetes in the USA. The UAE was the first country to approve its use for weight loss, with Kings College Hospital London being among the pioneers to introduce it. Dr Khan has been utilising this medication for over a year, showcasing its effectiveness.

Medical supervision and prescription:

Dr Khan emphasised the necessity of medical supervision and a prescription from an experienced endocrinologist. While Zepbound/Mounjaro has demonstrated significant results, it, like any medication, comes with side effects that require careful monitoring. The Kings College Hospital Diabetes and Endocrine Centre (KIDEO) boasts a team of UK-qualified consultants experienced in administering this innovative treatment.

Effectiveness and mechanism of Zepbound/Mounjaro:

Zepbound/Mounjao acts on gut hormones GLP-1 and GIP, reducing gastric emptying, prolonging food in the stomach, and signalling the brain to diminish appetite and cravings. Dr Khan highlighted its exceptional effectiveness, with patients experiencing a substantial reduction in food intake and cravings for certain foods.

Zepbound/Mounjaro is administered through a once-weekly self-injection. The duration of use varies based on individual circumstances, with some patients opting for short-term use while incorporating lifestyle changes. The decision for long-term use is made in consultation with an endocrinologist, and the KIDEO team at King’s House UK trained consultant is ready to support patients on their weight loss journey.